FDA Clearance Tracker · P140009-S087
Liberta RC DBS IPG ,Charger Kit - Pectoral ,Patient Controller Application ,Clinician Programmer Application
Last checked: Nov 20, 2026Latest source record: Jan 24, 2024 (this decision)Source: openFDAMethods & limitations
Decided
Jan 24, 2024
Approved
Time to decision
180 days
Received Jul 28, 2023. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P140009-S087
- Device name
- Liberta RC DBS IPG ,Charger Kit - Pectoral ,Patient Controller Application ,Clinician Programmer Application
- Applicant
- ABBOTT MEDICAL
- Applicant location
- Plano, TX
- Received
- Jul 28, 2023
- Decided
- Jan 24, 2024
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P140009
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
For P140009/S087, approval for: The Liberta RCTM DBS System, including the Liberta RC DBS IPG (model 62400) and Charger Kit Pectoral (model 66000) Patient Controller Application version 2.0 and Clinician Programmer Application version 2.0 including the NeuroshpereTM Virtual Clinic Alternate resistor component changes in the printed circuit board assembly (PCBA) for the Liberta RC DBS IPG (model 62400) An alternate cell battery part number from an existing supplier for Charger Model 16000 when used with the Liberta RC DBS SystemFor P010032/S202, approval for: Patient Controller Application version 2.0 and Clinician Programmer Application version 2.0 including the NeuroshpereTM Virtual Clinic and FlexBurst360TM programming Change the requirement regarding MRI mode during charging in the Eterna SCS System to align with the Liberta RC DBS System
Source documents
Other decisions for ABBOTT MEDICAL
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P260019 · Decided Oct 27, 2026 · 180 days after receipt
Device type: Para-device leak occluder (SJT) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.